|
1）Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014; 371: 906-17
|
|
|
|
2）ノバルティス．ファリーダック®カプセル10mg, 15mg添付文書. 2015年7月作成
|
|
|
|
|
|
3）San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014; 15: 1195-206
|
|
|
|
|
|
4）Millennium Pharmaceuticals, Inc. A phase 3 study comparing oral MLN9708 plus lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma. In: ClinicalTrials. gov [Internet]. National Library of Medicine (US), http: //clinicaltrials. gov/ct2/show/NCT01564537?term1/4
|
|
|
|
|
|
5）Handa H, Suzuki K, Chou T, et al. Phase 1 study of the investigational proteasome inhibitor ixazomib alone or in combination with lenalidomide-dexamethasone (Rd) in Japanese patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM). Blood. 2014; 124; 5752
|
|
|
|
|
|
6）Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014; 15: 1503-12
|
|
|
|
|
|
7）Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372: 142-52
|
|
|
|
|
|
8）Dimopoulous MA, et al. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients relapsed multiple myeloma: results from the phase 3 study ENDEVOR. ASCO Meet 2015
|
|
|
|
|
|
9）Intergroupe Francophone du Myélome 2009-02. Leleu X, Attal M, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Blood. 2013; 121: 1968-75
|
|
|
|
|
|
10）Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN. ). Br J Haematol. 2014; 164: 811-21
|
|
|
|
|
|
11）San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; 14: 1055-66
|
|
|
|
|
|
12）Suzuki K, Ogura M, Abe Y, et al. Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. Int J Hematol. 2015; 101: 286-94
|
|
|
|
|
13）van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011; 96: 284-90
|
|
|
|
|
|
14）ASCO Meet Abstr 2013; 31(15_suppl): 8512
|
|
|
|
|
|
15）Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008; 14: 2775-84
|
|
|
|
|
|
16）Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015; 373: 621-31
|
|
|
|
|
|
17）Koizumi F, Kitagawa M, Negishi T, et al. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 2006; 66: 10048-56
|
|
|
|
|
|
18）Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46: 6387-92
|
|
|
|
|
|
19）Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev. 2011; 63: 184-92
|
|
|
|
|
|
20）Miyazaki O, Sekine K, Nakajima N, et al. Antimyeloma activity of NK012, a micelle-forming macromolecular prodrug of SN-38, in an orthotopic model. Int J Cancer. 2014; 134: 218-23
|
|
|
|
|
|
21）鈴木憲史，畠 清彦，張 高明，他．多発性骨髄腫に対するNK012の第I相臨床試験 第112回日本内科学会総会
|
|
|
|
|
|
22）Auner HW, Cenci S. Recent advances and future directions in targeting the secretory apparatus in multiple myeloma. Br J Haematol. 2015; 168: 14-25
|
|
|
|
|
|
23）Pönisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006; 132: 205-12
|
|
|
|
|
|
24）Ponisch W, Rozanski M, Goldschmidt H, et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a phase I clinical trial. Br J Haematol. 2008; 143: 191-200
|
|
|
|
|
|
25）Ponisch W, Heyn S, Beck J, et al. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. Br J Haematol. 2013; 162: 202-9
|
|
|
|
|